Abstract: Retinoid antagonist compounds have been found to be useful in the prevention and/or minimization of surgical adhesion formation.
Also provided by the invention are certain novel substituted (5,6)-dihydronaphthalenyl compounds which are retinoid antagonists and possess the above-mentioned property in addition to their use as antiinflammatory agents for chronic skin inflammatory diseases, as agents for the treatment of rheumatic diseases and as agents for the treatment of various tumors as well as non-malignant proliferative skin conditions.
Type:
Grant
Filed:
December 8, 2000
Date of Patent:
November 20, 2001
Assignee:
Bristol-Myers Squibb Company
Inventors:
Kenneth M. Tramposch, Xina Nair, Anne Marinier, Fred Christopher Zusi
Abstract: The novel antitumor antibiotics designated stephacidin A and stephacidin B are produced by fermentation of Aspergillus ochraceus ATCC-74432. The antibiotics inhibit the growth of mammalian tumors, including particularly prostate carcinoma.
Type:
Grant
Filed:
September 7, 1999
Date of Patent:
September 18, 2001
Assignee:
Bristol-Myers Squibb Company
Inventors:
Jingfang Qian Cutrone, Kimberly D. Krampitz, Yue-Zhong Shu, Li-Ping Chang, Susan E. Lowe
Abstract: Provided by the present invention are cephem derivatives represented by the general formula
wherein Ar is an optionally substituted lipophilic phenyl, naphthyl or pyridyl group; L1 and L2 are (C1-C6)alkylene optionally substituted with hydroxy or oxo and/or optionally interrupted with a vinylene group, S, O, aryl, heteroaryl,
in which R1 is H or (C1-C6)alkyl; A is CO2H, PO3H, SO3H, tetrazolyl or
x′{circle around (−)} is a pharmaceutically acceptable anion; and Q is an quaternized nitrogen group. The derivatives are gram-positive antibacterial agents especially useful in the treatment of diseases caused by methicillin-resistant Staphylococcus aureus.
Type:
Grant
Filed:
August 4, 1999
Date of Patent:
July 24, 2001
Assignee:
Bristol-Myers Squibb Company
Inventors:
Roman Z. Sterzycki, Oak K. Kim, Yasutsugu Ueda, Stanley V. D'Andrea, Dane M. Springer
Abstract: Water-soluble prodrugs of triazole antifungal compounds having a secondary or tertiary hydroxy group are provided. More particularly, new water-soluble triazole antifungal compounds are provided having the general formula
wherein A is the non-hydroxy portion of a triazole antifungal compound of the type containing a secondary or tertiary hydroxyl group and n, R1 and R2 are as defined in the specification.
Type:
Grant
Filed:
May 20, 1999
Date of Patent:
July 24, 2001
Assignee:
Bristol-Myers Squibb Company
Inventors:
Thomas W. Hudyma, Oak K. Kim, Xiaofan Zheng
Abstract: Water soluble prodrugs of azole antifungal agents are provided by quaternizing a nitrogen atom of the azole ring with a phosphonooxymethyl group.
Type:
Grant
Filed:
February 11, 2000
Date of Patent:
May 22, 2001
Assignee:
Bristol-Myers Squibb Company
Inventors:
Jerzy Golik, John D. Matiskella, Yasutsugu Ueda
Abstract: A high drug load enteric coated pharmaceutical composition is provided which includes a core comprised of a medicament which is sensitive to a low pH environment of less than 3, such as ddl, which composition is preferably in the form of beadlets having an enteric coating formed of methacrylic acid copolymer, plasticizer and an additional coat comprising an anti-adherent. The so-called beadlets have excellent resistance to disintegration at pH less than 3 but have excellent drug release properties at pH greater than 4.5. A novel method of making said pharmaceutical composition is also disclosed.
Abstract: Provided are very highly water soluble, stable, crystalline salts of 2′,3′-dideoxy-2′,3′-didehydrothymidine (“d4T”), 2′,3′-dideoxyinosine (“ddI”), and 2′,3′-dideoxy-2′-fluoroinosine (“F-ddI”). Such salts are useful as intermediates or as antiviral agents.
Type:
Grant
Filed:
December 6, 1991
Date of Patent:
March 27, 2001
Assignee:
Bristol-Myers Squibb Company
Inventors:
Joseph B. Bogardus, Murray A. Kaplan, Robert K. Perrone
Abstract: The 5,6-dihydronaphthalenyl derivatives of the formulae
possess potent retinoid-like activity against dermatological diseases with a substantially reduced irritancy profile when administered topically.
Type:
Grant
Filed:
September 16, 1999
Date of Patent:
February 27, 2001
Assignee:
Bristol-Myers Squibb Company
Inventors:
Anne Marinier, Yong-Jiang Hei, Philippe Lapointe, Jean-Paul Daris
Abstract: Disclosed is a process for the synthesis of .beta.-lactam antibacterials using soluble side chain esters in the presence of enzyme acylase. Also disclosed are novel esters useful as reactants in said process.
Abstract: Novel suppository pharmaceutical formulations of the platinum antitumor agent, JM216, are provided. Such dosage forms provide an alternative to the oral form currently available and offer improved bioavailability of this promising drug.
Abstract: The present invention provides the crystalline bisulfate salt of the formula ##STR1## which is found to have unexpectedly high solubility/dissolution rate and oral bioavailability relative to the free base form of this azapeptide HIV protease inhibitor compound.
Type:
Grant
Filed:
December 21, 1998
Date of Patent:
July 11, 2000
Assignee:
Bristol-Myers Squibb Company
Inventors:
Janak Singh, Madhusudhan Pudipeddi, Mark D. Lindrud
Abstract: The present invention relates to a compound of the formula ##STR1## wherein X is --CONH-- or --NHCO--, or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof.The compounds of the present invention exhibit retinoid-like properties and are thus useful as antiinflammatory agents for chronic skin inflammatory diseases such as psoriasis and atopic dermatitis, as agents for the treatment of rheumatic diseases such as rheumatoid arthritis, as antitumor agents for the treatment of various tumors, and as agents for the treatment of non-malignant proliferative skin conditions.
Type:
Grant
Filed:
March 27, 1998
Date of Patent:
December 28, 1999
Assignee:
Bristol-Myers Squibb Company
Inventors:
Fred C. Zusi, Peter R. Reczek, Jacek Ostrowski
Abstract: A novel class of antibiotics, designated bravomicins, is obtained by fermentation of a strain of Micromonospora polytrota. Six bioactive compounds, designated bravomicins A, B, C, D, E and F, are obtained and found to be useful in the treatment of a wide variety of bacterial diseases.
Type:
Grant
Filed:
March 4, 1999
Date of Patent:
November 30, 1999
Assignee:
Bristol-Myers Squibb Company
Inventors:
Yue-Zhong Shu, Jie Chen, Kin Sing Lam, Judith A. Veitch, Daniel Brown
Abstract: Certain novel substituted (5,6)-dihydroanthracenyl compounds of the general formula ##STR1## wherein A, n, p, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are as defined in the specification exhibit retinoid-like properties and are particularly useful in the prevention of post-surgical adhesions.
Type:
Grant
Filed:
April 24, 1998
Date of Patent:
August 31, 1999
Assignee:
Bristol-Myers Squibb Company
Inventors:
John E. Starrett, Jr., Kenneth M. Tramposch, Xina Nair, Peter R. Reczek, Anna Ericsson, Anne Marinier, Alain Martel, Fred C. Zusi
Abstract: The present invention relates to the novel antitumor antibiotic designated BMS-199687 and to its preparation. The compound is obtained by culturing a new strain of Actinomadura ferruginea. BMS-199687 demonstrates antitumor activity in standard antitumor animal model systems.
Type:
Grant
Filed:
February 13, 1998
Date of Patent:
July 6, 1999
Assignee:
Bristol-Myers Squibb Company
Inventors:
Mitsuaki Tsunakawa, Li-Ping Chang, Stephen W. Mamber, Isia Bursuker, Robert Hugill
Abstract: This invention relates to a compound of formula I ##STR1## in which T is --CONH-- or --CH=CH--;R.sup.a and R.sup.b are independently C.sub.1-6 alkyl;R.sup.C is C.sub.1-6 alkyl or hydrogen; andR is heteroaryl.
Type:
Grant
Filed:
June 4, 1996
Date of Patent:
December 15, 1998
Assignee:
Bristol-Myers Squibb Company
Inventors:
John E. Starrett, Jr., David R. Tortolani, Muzammil M. Mansuri, Nicholas A. Meanwell
Abstract: This invention provides a novel series of taxane derivatives which are characterized by the C3' nitrogen bearing one or two sulfur substituents. The new derivatives are antitumor agents useful in the treatment of such cancers as ovarian, breast, lung, gastric, colon, head and neck, melanoma and leukemia.
Abstract: The present invention relates to the novel antitumor antibiotic designated BMS-199687 and to its preparation. The compound is obtained by culturing a new strain of Actinomadura ferruginea. BMS-199687 demonstrates antitumor activity in standard antitumor animal model systems.
Type:
Grant
Filed:
April 2, 1997
Date of Patent:
September 22, 1998
Assignee:
Bristol-Myers Squibb Company
Inventors:
Mitsuaki Tsunakawa, Li-Ping Chang, Stephen W. Mamber, Isia Bursuker, Robert Hugill
Abstract: The cephalosporin intermediates, desacetyl 7-glutaryl ACA and desacetyl cephalosporin D, are obtained in the form of a concentrated aqueous solution from an aqueous solution containing said intermediates in less concentrated form by solvent extraction using cyclohexanone followed by back-extraction into water. The concentrated aqueous solution of intermediate is in a form which can be used for economical production of 7-ACA using known procedures.
Type:
Grant
Filed:
July 18, 1997
Date of Patent:
September 1, 1998
Assignee:
Bristol-Myers Squibb Company
Inventors:
Gary M. F. Lim, John M. Roubie, Vicki H. Audia